Page 5,779«..1020..5,7785,7795,7805,781..5,7905,800..»

Research to boost production of stem cells

Posted: Published on February 1st, 2013

A revolutionary stem cell treatment using umbilical cord blood will be investigated by a Melbourne researcher. The work has the potential to help people who require bone marrow transplants but struggle to find an exact match. Associate Professor Louise Purton from St Vincent's Institute in Melbourne will use compounds derived from vitamin A to increase the number and quality of cord blood stem cells. Stem cells from cord blood are becoming increasing popular for bone marrow transplants around the world. But often there are not enough stem cells from a single unit for a successful transplant for an adult, although some patients are infused with two unrelated cord blood units with varying degrees of success. Cord blood cells can be slow to mature into platelets and red and white blood cells, which can leave the patient exposed to a greater risk of infection. Donor, or allogeneic, cord blood also carries the risk of graft versus host disease, where the recipient's immune system responds to the foreign cells by attacking the body's organs. Assoc Prof Purton has proven her method works in mice and will now move to test the compounds on human cord blood. "One of the goals in the … Continue reading →

Posted in Stem Cell Research | Comments Off on Research to boost production of stem cells

Stem cell agency to change grant system

Posted: Published on February 1st, 2013

The governing board of California's stem cell funding agency has voted to overhaul how it distributes scientific grants after critics raised concerns that too many board members represented schools that have won funding. The final proposal is expected to be decided by a vote on March 13, and if accepted would bar California Institute for Regenerative Medicine board members associated with grant-eligible institutions from voting on where the money goes. Thirteen of the 29 board members are associated with schools that receive grants, which have raised concerns over conflicts of interest, the San Francisco Chronicle reported. The members represent a many constituencies, including patient advocates and representatives from the biotech industry and research institutions. The vote follows a report by the Institute of Medicine that found the agency should restructure its system for distributing grants. The study did not find specific conflicts, but said the appearance of a conflict could hamper the agency's future goals. The stem cell agency was created in 2004 after state voters approved Proposition 71, which funded human embryonic stem cell research at a time when there were federal restrictions and opposition from some religious groups. The agency has broad powers to distribute $3 billion in … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem cell agency to change grant system

Cutting Edge Research in Stem Cells and Cancer Immunotherapy to Be Presented at the 2nd Annual Cancer Immunotherapy …

Posted: Published on February 1st, 2013

MINNEAPOLIS--(BUSINESS WIRE)-- Ground breaking research on cancer stem cells as targets and normal stem cells in Immunotherapy will be discussed at the 2nd Annual Cancer Immunotherapy Conference in Washington DC on April 4-5, 2013. As modern oncology, largely directed towards developing therapies that achieve tumor reduction, has been thus far unsuccessful in achieving long term management of cancer, much more needs to be done in identifying and appropriately leveraging targets associated with tumor initiation, relapse or metastasis. Immunotherapy holds the promise of achieving durable control of cancer if matched with appropriate targets borne by cancer cells responsible for relapse and metastasis. At the 2nd Annual Cancer Immunotherapy Conference, significant findings on hematopoietic stem cells and T cell engineering for cancer immunotherapy, as well as cancer stem cells as a new category of targets for immune intervention in solid and hematological malignancies will be presented by nearly twenty experts in the fields of academia, pharmaceuticals and cancer research. Speakers and panelists will be addressing and answer the following questions: Some of the speakers at this years conference include: This conference brings together leading scientists and C-Level executives from across the globe to present ground breaking research, case studies and new viewpoints. … Continue reading →

Posted in Stem Cell Research | Comments Off on Cutting Edge Research in Stem Cells and Cancer Immunotherapy to Be Presented at the 2nd Annual Cancer Immunotherapy …

Stem cell research helps find origins of schizophrenia

Posted: Published on February 1st, 2013

Arrows point to cell nuclei in human embryonic stem cells in which a fibroblast growth factor receptor protein, (FGFR1), targets diverse genes implicated in schizophrenia. New UB research demonstrates how defects in an important neurological pathway in early development may be responsible for the onset of schizophrenia later in life. The UB findings, published in Schizophrenia Research, test the hypothesis in a new mouse model of schizophrenia that demonstrates how gestational brain changes cause behavioral problems later in lifejust like the human disease. Partial funding for the research came from New York Stem Cell Science (NYSTEM). The genomic pathway, called the Integrative Nuclear FGFR 1 Signaling (INFS), is a central intersection point for multiple pathways of as many as 160 different genes believed to be involved in the disorder. We believe this is the first model that explains schizophrenia from genes to development to brain structure and finally to behavior, says lead author Michal Stachowiak, professor in the Department of Pathology and Anatomical Sciences, School of Medicine and Biomedical Sciences. He also is director of the Stem Cell Engraftment & In Vivo Analysis Facility at the Western New York Stem Cell Culture and Analysis Center at UB. A key challenge … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem cell research helps find origins of schizophrenia

Family practice offers genetic tests to predict effective psychiatric meds, a CAMH study

Posted: Published on February 1st, 2013

Public release date: 30-Jan-2013 [ | E-mail | Share ] Contact: Michael Torres media@camh.ca 416-595-6015 Centre for Addiction and Mental Health For the first time in Canada, patients attending a family practice clinic will be offered genetic testing to see whether or how they will respond to psychiatric medication treatment, in partnership with the Centre for Addiction and Mental Health (CAMH). Thornhill Medical Centre, a clinic of family physicians, is making the promise of personalized medicine a reality. "These pharmacogenetic tests will enable physicians to use a patient's genetic makeup to help predict which medications are safe to prescribe, and which ones may be ineffective or cause side effects," said Dr. James Kennedy, head of CAMH's Neuroscience Research Department. The tests, which will prevent trial-and-error prescribing and reduce associated health-care costs, will be analyzed in the Tanenbaum Centre for Pharmacogenetics at CAMH's Campbell Family Mental Health Research Institute. "My patients were ready for these tests yesterday they may have tried three or four different antidepressants that didn't work or had side effects, before finding something that helped them," Dr. Nick Voudouris, a family physician with the Thornhill Medical Centre. "The ability to be able to know which medications patients will … Continue reading →

Comments Off on Family practice offers genetic tests to predict effective psychiatric meds, a CAMH study

ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

Posted: Published on February 1st, 2013

SAN DIEGO, Jan. 31, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted 20 patents worldwide in 2012, eight U.S. and twelve foreign. These patents bolster the Company's already strong proprietary position for its ground-breaking diabetes product, VC-01, as well as other applications of its broad technology platform. (Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a) VC-01 is a very promising, development-stage product that consists of pancreatic precursor cells (called PEC-01) derived from a proprietary human embryonic stem cell line and encapsulated in a proprietary, immune isolating medical device (the ENCAPTRA device). When implanted under the skin in suitable animal models, the cells further differentiate into insulin producing and other endocrine cells that regulate blood glucose in a manner similar or identical to a normal pancreas. If VC-01 performs in humans as it has in animal studies, it could effectively cure type 1 diabetics and be an important new therapy for insulin dependent type 2 diabetics. ViaCyte's significant intellectual property portfolio now includes over 300 issued patents and pending applications related to the growth, directed differentiation and use of human … Continue reading →

Comments Off on ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

PRESS RELEASE: MagForce starts research project with University of Bremen

Posted: Published on February 1st, 2013

MagForce AG / MagForce starts research project with University of Bremen . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. * Project to develop magnetic iron oxide particles with improved efficiency * Agreement on funding by German Federal Ministry of Economics and Technology from the German Mittelstand innovation program "Zentrales Innovationsprogramm Mittelstand (ZIM)" Berlin, Germany, January 31, 2013 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, today announced the start of a research project with the University of Bremen, Center for Environmental Research and Sustainable Technology, for the development of magnetic iron oxid particles with improved efficiency. The novel particles will allow a more efficient treatment of abdominal cancers, such as prostate and pancreatic cancer. A more efficient magnetic fluid and a pilot manufacturing facility will result from the collaboration. The project will receive funding from the German Mittelstand Innovation Program (ZIM) which is managed by the German Federal Ministry of Economics and Technology and will run for two years. "We are excited to be working with Prof Dr Jorg Thming, who is an internationally renowned expert in the area … Continue reading →

Comments Off on PRESS RELEASE: MagForce starts research project with University of Bremen

MagForce starts research project with University of Bremen

Posted: Published on February 1st, 2013

Project to develop magnetic iron oxide particles with improved efficiency Agreement on funding by German Federal Ministry of Economics and Technology from the German Mittelstand innovation program "Zentrales Innovationsprogramm Mittelstand (ZIM)" Berlin, Germany, January 31, 2013 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, today announced the start of a research project with the University of Bremen, Center for Environmental Research and Sustainable Technology, for the development of magnetic iron oxid particles with improved efficiency. The novel particles will allow a more efficient treatment of abdominal cancers, such as prostate and pancreatic cancer. A more efficient magnetic fluid and a pilot manufacturing facility will result from the collaboration. The project will receive funding from the German Mittelstand Innovation Program (ZIM) which is managed by the German Federal Ministry of Economics and Technology and will run for two years. "We are excited to be working with Prof Dr Jorg Thming, who is an internationally renowned expert in the area of process engineering, as a cooperation partner. This project is perfectly in-line with MagForce`s new strategy to conduct early-stage research and development collaborations with academic institutions", commented Prof Dr Hoda Tawfik, COO … Continue reading →

Comments Off on MagForce starts research project with University of Bremen

NEWEST Watermelon as Treatment for Erectile Dysfunction :P – Video

Posted: Published on January 31st, 2013

NEWEST Watermelon as Treatment for Erectile Dysfunction 😛 Using a hypoglycemia diet (www.hypoglycemicdiet.net )plan's often the way diabetics keep their all forms of diabetes in check, but it is another good way for those not necessarily suffering from diabetes to be able to shed those extra/unwanted kilos. A hypoglycemia diet operates by slowing down that fee in which the body soaks in glucose, which in turn causes our bodies to burn calories which can be stored in your fat tissues. You need to understand exactly what hypoglycemia is needed to have a successful hypoglycemia diet program. Hypoglycemia is a condition the location where the blood sugar levels (or sugar levels) become too low within the body and ultimately your brain, which leads to a variety of unpleasant symptoms including: tiredness, blurred vision, quick heart rate, headache...etc. This can be due to glucose being released also slowly into the blood vessels or by a lot of insulin being released to the bloodstream. A blood sugar level that is with or below 70mg/dL is recognized as low and can become harmful to the body. Make sure you consult your physician prior to starting a hypoglycemia diet, there could be certain foods … Continue reading →

Posted in Erectile Dysfunction | Comments Off on NEWEST Watermelon as Treatment for Erectile Dysfunction :P – Video

Erectile Dysfunction Linked To Heart Disease

Posted: Published on January 31st, 2013

Editor's Choice Academic Journal Main Category: Erectile Dysfunction / Premature Ejaculation Also Included In: Heart Disease Article Date: 30 Jan 2013 - 10:00 PST Current ratings for: Erectile Dysfunction Linked To Heart Disease 4.5 (2 votes) The finding came from a new study conducted by researchers from the Australian National University, led by Emily Banks, and was published in PLOS Medicine. Prior research has demonstrated that erectile dysfunction is associated with heart disease risk. In fact, a study from August of last year demonstrated that erectile dysfunction is a risk factor in men aged 55 or younger for eventual heart disease. However, this is the first study to indicate that the severity of ED correlates with the elevated chance of CVD hospitalization and all-cause mortality. ''The risks of future heart disease and premature death increased steadily with severity of erectile dysfunction,'' Emily Banks explained. The team of investigators gathered and examined date from the Australian prospective cohort 45 and Up Study. The research consisted of 95,038 males aged 45 or older. After controlling for variables that could have an impact on the results, the experts analyzed the link between severity of self-reported ED and CVD hospitalization and mortality. Over 65,000 … Continue reading →

Posted in Erectile Dysfunction | Comments Off on Erectile Dysfunction Linked To Heart Disease

Page 5,779«..1020..5,7785,7795,7805,781..5,7905,800..»